Novo Nordisk disclosed an “unauthorized access” incident involving certain clinical trial data for products including Ozempic and Wegovy. The company said direct identifiers such as patients’ names were not affected and that participants face no immediate risks, while it continues an investigation with external cybersecurity experts and notifies relevant authorities. The disclosure raises renewed attention on data security across trial ecosystems.